Arena Pharmaceuticals (NASDAQ:ARNA) shares have jumped 170.13 percent over the trailing 6 months.
Vivus (NASDAQ:VVUS) has enjoyed higher than anticipated support for its new Qsymia drug on its first week on the market.
Dendreon Corporation (NASDAQ:DNDN) is getting bets from options traders are gambling on support for the firm, as shown by Tuesday’s desire for short puts. At the close, the company had seen approximately 12,000 puts cross the tape, which is around 13 times its average daily put volume, and almost three times the number of Dendreon calls exchanged.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical firm concentrating uopn developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, announced Tuesday that it has priced a direct public offering of about 6.3 million shares of its common stock to certain affiliates of Ayer Capital, RA Capital and Quaker Partners, at $4.07 per share, which was the consolidated closing bid on the NASDAQ Capital Market on September 27th with gross proceeds to Insmed of $25.7 million.
Merck & Co. (NYSE:MRK) is partnering with the Belgian drug developer Ablynx (ABLX.BR) in an arrangement potentially worth €448 million, or $578.15 million. The biotechnology company which is based in Ghent, listed on Euronext Brussels in November 2007. The firm reported that upon signing of the agreement, it would receive a €6.5 million initial payment along with €2 million for research funding.
Don’t Miss: What’s Next for Pfizer?